Tobias Reichlin.

This multicenter research corroborated the hypothesis that cardiac troponin assays with an increase of sensitivity would improve the early diagnosis of severe myocardial infarction.4,13-15,17-21,25 We also confirm and extend findings from two recent single-center pilot studies evaluating the Siemens Troponin I Ultra assay.20,21 Third, the superiority of the sensitive cardiac troponin assays was most pronounced among individuals with a recently available onset of chest pain.2-4 More rapid medical diagnosis of acute myocardial infarction may reduce complications by allowing for earlier revascularization, earlier transfer to the coronary care unit, and earlier initiation of evidence-based treatment for acute myocardial infarction.2-4 Fourth, the sensitive cardiac troponin assays may make it feasible to reliably eliminate the diagnosis of severe myocardial infarction in lots of patients on the basis of the initial measurement.Together with its availability in pharmacies nationwide, AVANIR’s sales team will commence advertising on February 7, 2011 to neurologists, psychiatrists and various other physicians who treat individuals with PBA secondary to underlying neurologic conditions such as multiple sclerosis , amyotrophic lateral sclerosis , traumatic brain injury , stroke, Parkinson’s disease and certain other neurologic diseases. The national launch of NUEDEXTA is being supported by 75 specialty sales representatives, nearly all whom possess significant prior experience selling CNS therapies to the psychiatry and neurology audiences.